XML 44 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Quarterly Financial Data (Unaudited)
12 Months Ended
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Data (Unaudited)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
(amounts in thousands, except per share data)
Revenue from services
$
207,573

 
$
209,313

 
$
228,488

 
$
219,674

 
 
 
 
 
 
 
 
Gross profit (a)
53,275

 
56,528

 
60,480

 
58,303

 
 
 
 
 
 
 
 
Consolidated net (loss) income
(1,718
)
 
5,220

 
7,044

 
28,256

 
 
 
 
 
 
 
 
Net (loss) income attributable to common shareholders
(2,010
)
 
4,850

 
6,723

 
27,950

 
 
 
 
 
 
 
 
Net (loss) income per share attributable to common shareholders - Basic
$
(0.06
)
 
$
0.14

 
$
0.19

 
$
0.78

 
 
 
 
 
 
 
 
Net (loss) income per share attributable to common shareholders - Diluted
$
(0.08
)
 
$
0.13

 
$
0.19

 
$
0.77

 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2016
(amounts in thousands, except per share data)
Revenue from services
$
196,583

 
$
199,443

 
$
214,988

 
$
222,523

 
 
 
 
 
 
 
 
Gross profit (a)
51,046

 
54,846

 
58,210

 
57,633

 
 
 
 
 
 
 
 
Consolidated net income (loss)
19,186

 
(17,095
)
 
14,289

 
(7,649
)
 
 
 
 
 
 
 
 
Net income (loss) attributable to common shareholders
19,022

 
(17,237
)
 
14,066

 
(7,884
)
 
 
 
 
 
 
 
 
Net income (loss) per share attributable to common shareholders - Basic
$
0.60

 
$
(0.54
)
 
$
0.44

 
$
(0.24
)
 
 
 
 
 
 
 
 
Net income (loss) per share attributable to common shareholders - Diluted
$
0.09

 
$
(0.54
)
 
$
0.22

 
$
(0.24
)
________________

(a) Excludes depreciation and amortization.

The following items impact the comparability and presentation of our consolidated data:

The Company recorded changes in the fair value of Convertible Notes derivative liability, recording a gain in the first quarter of 2017 of $1.6 million, a gain in the first and third quarters of 2016 of $16.4 million and $7.1 million, respectively, and a loss in the second and fourth quarters of 2016 of $3.6 million and $14.2 million, respectively. See Note 9 - Convertible Notes Derivative Liability.
During the fourth quarter of 2017 and the second quarter of 2016, the Company recorded non-cash impairment charges of $14.4 million and $24.3 million, respectively. See Note 5 - Goodwill, Trade Names, and Other Intangible Assets.
During the first quarter of 2017, the Company settled its Convertible Notes and recognized a loss on extinguishment of debt of $5.0 million. During the second quarter of 2016, the Company repaid its Second Lien Term Loan and recognized a loss on extinguishment of debt of $1.6 million. See Note 8 - Debt.
On July 1, 2017, the Company acquired all of the assets of Advantage. The acquisition has been accounted for in accordance with the Business Combinations Topic of the FASB ASC, using the acquisition method. The results of the acquisition's operations have been included in the consolidated statements of operations from its date of acquisition. See Note 3 - Acquisitions.
In 2017 and 2016, the Company recorded acquisition-related contingent consideration expense primarily related to the Mediscan and USR acquisitions, recording expense of $0.3 million in the first and second quarters of 2017, a credit of $0.6 million in the third quarter of 2017, and expense of $0.1 million in the fourth quarter of 2017, and expense of $0.3 million in the first quarter of 2016, $0.2 million in the second and third quarters of 2016, and $0.1 million in the fourth quarter of 2016. See Note 3 - Acquisitions and Note 10 - Fair Value Measurements.
In the third and fourth quarters of 2017, the Company recorded restructuring costs of $0.7 million and $0.3 million, respectively, primarily related to a cost saving initiative, and in the third and fourth quarters of 2016, $0.6 million and $0.2 million, respectively, primarily related to the centralization of corporate functions. See Note 2 - Summary of Significant Accounting Policies.
In the fourth quarter of 2017, the Company benefited from a $43.3 million reversal of valuation allowance on its net deferred tax assets, offset by additional income tax expense of $8.0 million related to the remeasurement of its deferred tax assets as a result of the 2017 Tax Act. See Note 13 - Income Taxes.